Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Huangdai Tablet
- Development stage
- Phase 4
- Lead developer
- Yifan Pharmaceutical
- Modality
- Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
Compound Huangdai Tablet is an oral combination medicine used primarily for the treatment of acute promyelocytic leukemia (APL). It is also known as the Realgar-Indigo Naturalis formula (RIF) and consists of realgar (tetraarsenic tetrasulfide), Indigo naturalis (containing indirubin), root of Salvia miltiorrhiza (providing tanshinone IIA), and root of Pseudostellaria heterophylla. The main mechanism involves breaking down the cancer protein retinoic acid receptor alpha and regulating multiple molecular pathways to induce apoptosis and inhibit proliferation in APL cells. Its efficacy is considered similar to arsenic trioxide when combined with all-trans-retinoic acid (ATRA), but it offers advantages such as lower risk of liver dysfunction, greater convenience due to oral administration, and reduced cost. Developed in China in the 1980s and approved there in 2009, it appears on the World Health Organization's List of Essential Medicines[1][2][3][8].
- Brand names
- Compound Huangdai Tablet
- Other names
- Realgar–Indigo naturalis formulation复方黄黛RIF
02
Targets
RARA (Retinoic acid receptor alpha)NCOA2 (Nuclear receptor coactivator 2)PML-RARA (PML-retinoic acid receptor alpha fusion protein)
Beyond the preview
Go deeper on Compound Huangdai Tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound Huangdai Tablet.